Adolescents face compounded GLP-1 eating disorder risk because ED prevalence peaks during adolescence while social media exposure is highest
Developmental timing creates a double exposure: adolescence is both the peak ED onset period and the demographic with highest social media use driving cosmetic GLP-1 demand
Claim
The review identifies adolescents as the highest-risk population for GLP-1-induced eating disorder harm through a developmental timing mechanism. Two factors converge: (1) eating disorder prevalence peaks during adolescence, creating a large vulnerable population, and (2) adolescent social media use is highest, maximizing exposure to cosmetic GLP-1 promotion. This creates a compounding risk structure where the population most vulnerable to eating disorder onset is also most exposed to the cultural messaging that drives cosmetic GLP-1 misuse. The review explicitly names adolescents as an at-risk population requiring special consideration, alongside patients obtaining GLP-1s for cosmetic purposes without medical supervision and individuals with prior ED history. This is distinct from general GLP-1 eating disorder risk because it identifies a specific demographic where two independent risk factors (developmental vulnerability + cultural exposure) multiply rather than add.
Supporting Evidence
Source: PMC12835689, January 2026
Adolescent case progressed from prescription to life-threatening cardiac complications (bradycardia 38 bpm, pericardial effusion) within 6 months, demonstrating rapid escalation in developmentally vulnerable population. Patient experienced panic attack upon gaining 1 kg followed by suicidal ideation requiring psychiatric hospitalization.
Sources
1- 2025 xx pmc glp1 eating disorders double edged sword
inbox/queue/2025-xx-pmc-glp1-eating-disorders-double-edged-sword.md
Reviews
1## Leo's Review **1. Schema:** All files are claims (type: claim) with complete frontmatter including type, domain, confidence, source, created, and description fields—schema is valid for claim content type. **2. Duplicate/redundancy:** The new claims introduce distinct mechanisms (developmental timing convergence, social media pathway) while the enrichments add case evidence and regulatory context not present in original claim text—no redundancy detected. **3. Confidence:** All claims use "experimental" confidence, which is appropriate given the source is a 2025 systematic narrative review documenting pharmacovigilance signals, case reports, and theoretical mechanisms rather than RCT evidence. **4. Wiki links:** Multiple broken wiki links exist ([[glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive]], [[glp1-social-media-cosmetic-misuse-creates-eating-disorder-pathway]], [[ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures]]) but these are expected in multi-PR workflows and do not affect approval. **5. Source quality:** PMC/Journal of Clinical Medicine systematic narrative review (2025) is a credible peer-reviewed source appropriate for health domain claims about pharmacological risks and clinical practice gaps. **6. Specificity:** Claims are falsifiable with specific mechanisms (developmental timing convergence, social media access without screening, subtype-specific pharmacology) and could be disproven by evidence showing no differential risk in adolescents or no ED onset via cosmetic access pathways. <!-- VERDICT:LEO:APPROVE -->